Literature DB >> 14622776

Sex differences in opioid antinociception in rhesus monkeys: antagonism of fentanyl and U50,488 by quadazocine.

S Stevens Negus1, David S Zuzga, Nancy K Mello.   

Abstract

Sex differences have been observed in the antinociceptive effects of opioids in rodents and rhesus monkeys. Sex differences in the affinity of opioid ligands for opioid receptors may contribute to these findings. To test this hypothesis, the relative affinity of the competitive opioid antagonist quadazocine for mu and kappa opioid receptors was determined in rhesus monkeys using in vivo pA(2) analysis. The antinociceptive effects of the mu opioid agonist fentanyl and the kappa opioid agonist U50,488 were determined alone and after pretreatment with quadazocine in 4 females and 4 males using a warm-water tail-withdrawal assay of thermal nociception. The relative potency of quadazocine antagonism of fentanyl and U50,488 in females and males was used to assess sex differences in the relative affinity of quadazocine for mu and kappa receptors. Fentanyl was equipotent in female and male monkeys, and quadazocine was equipotent as an antagonist of fentanyl in females and males. In contrast, U50,488 was significantly less potent in females, and quadazocine was less potent as an antagonist of U50,488 in females. These findings suggest that opioid ligands have similar affinity for mu receptors but lower affinity for at least some kappa receptors in female than in male rhesus monkeys.

Entities:  

Year:  2002        PMID: 14622776     DOI: 10.1054/jpai.2002.124734

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  16 in total

Review 1.  Sex Differences in Animal Models: Focus on Addiction.

Authors:  Jill B Becker; George F Koob
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

2.  Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Authors:  Kathryn L Schwienteck; S Stevens Negus; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

Review 3.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

4.  A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats.

Authors:  Jennifer M Mitchell; Marisa T Liang; Howard L Fields
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

6.  Sex difference in κ-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5'-O-(3-[35S]thiotriphosphate) binding in the guinea pig.

Authors:  Yu-Jun Wang; Khampaseuth Rasakham; Peng Huang; Darina Chudnovskaya; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2011-08-12       Impact factor: 4.030

7.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

8.  Modulation of delta opioid agonist-induced antinociception by repeated morphine pretreatment in rhesus monkeys.

Authors:  S S Negus; M L Banks; J E Folk; K C Rice
Journal:  Life Sci       Date:  2010-01-21       Impact factor: 5.037

Review 9.  Sex-based differences in pain perception and treatment.

Authors:  Channing J Paller; Claudia M Campbell; Robert R Edwards; Adrian S Dobs
Journal:  Pain Med       Date:  2009-01-16       Impact factor: 3.750

10.  Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.

Authors:  S Stevens Negus; Katrina Schrode; Glenn W Stevenson
Journal:  Exp Clin Psychopharmacol       Date:  2008-10       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.